Sertindole

Sertindole
Systematic (IUPAC) name
1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • AU: C
Routes of
administration		 Oral
Legal status
  • AU: S4 (Prescription only)
  • approved for marketing in approx. 20 countries
Pharmacokinetic data
Bioavailability 75%[1]
Protein binding 99.5%[1]
Metabolism Hepatic (mostly via CYP2D6 and CYP3A4)[2][3]
Biological half-life 3 days[2]
Excretion Faecal (the majority), Renal (4% metabolites; 1% unchanged)[2]
Identifiers
CAS Number 106516-24-9 YesY
ATC code N05AE03 (WHO)
PubChem CID 60149
IUPHAR/BPS 98
DrugBank DB06144 YesY
ChemSpider 54229 YesY
UNII GVV4Z879SP YesY
KEGG D00561 YesY
ChEBI CHEBI:9122 YesY
ChEMBL CHEMBL12713 YesY
Chemical data
Formula C24H26ClFN4O
Molar mass 440.941 g/mol
  (verify)

Sertindole (brand names: Serdolect and Serlect) is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.

Sertindole is not approved for use in the United States.

Medical Uses

Sertindole appears effective as an antipsychotic in schizophrenia.[4] It may have a favorable side effect profile, and efficacy similar to risperidone.[5]

Adverse effects

Very common (>10% incidence) adverse effects include:[2]

Common (1–10% incidence) adverse effects include:[2]

Uncommon (0.1–1% incidence) adverse effects include:[2]

  • Substernal chest pain
  • Face oedema
  • Influenza-like illness
  • Neck rigidity
  • Pallor
  • Peripheral vascular disorder
  • syncope
  • Torsades de pointes
  • Vasodilation
  • Suicide attempt
  • Amnesia
  • Anxiety
  • Ataxia
  • Confusion
  • Incoordination
  • Libido decreased
  • Libido increased
  • Miosis
  • Nystagmus
  • Personality disorder
  • Psychosis
  • Reflexes decreased
  • Reflexes increased
  • Stupor
  • Suicidal tendency
  • Urinary retention
  • Vertigo
  • Diabetes mellitus
  • Abnormal stools
  • Gastritis
  • Gingivitis
  • Glossitis
  • Increased appetite
  • Mouth ulceration
  • Rectal disorder
  • Rectal haemorrhage
  • Stomatitis
  • Tongue disorder
  • Ulcerative stomatitis
  • Anaemia
  • Ecchymosis
  • Hypochromic anaemia
  • Leukopenia
  • Hyperglycaemia
  • Hyperlipemia
  • Oedema
  • Bone pain
  • Myasthenia
  • Twitching
  • Bronchitis
  • Hyperventilation
  • Pneumonia
  • Sinusitis
  • Furunculosis
  • Herpes simplex
  • Nail disorder
  • Psoriasis
  • Pustular Rash
  • Skin discolouration
  • Skin hypertrophy
  • Skin ulcer
  • Abnormal vision
  • Keratoconjunctivitis
  • Lacrimation disorder
  • Otitis externa
  • Pupillary disorder
  • Taste perversion
  • Anorgasmia
  • Penis disorder (gs)
  • Urinary urgency
  • Hyperprolactinaemia (which it seems to cause with a higher propensity than most other atypical antipsychotics do[7])
  • Seizures
  • Galactorrhoea

Rare (<0.1% incidence) adverse effects include:[2]

Unknown frequency adverse events include:[2]

Pharmacology

Biologic protein Binding affinity (Ki[nM])[8] Notes
5-HT1A 280
5-HT1B 60
5-HT1D 96
5-HT1E 430
5-HT1F 360
5-HT2A 0.39 The receptor believed to mediate the atypicality of atypical antipsychotics.[9]
5-HT2C 0.9 Likely responsible for its propensity for causing weight gain.[9]
5-HT6 5.4
5-HT7 28
α1A 1.8 Likely responsible for the orthostatic hypotension seen in patients on sertindole.[9]
α2A 640
α2B 450
α2C 450
β1 5000
β2 5000
M1 >10000 [9]
M3 2692
D2 2.35 Believed to be responsible for the drug's efficacy against positive symptoms.[9]
D3 2.30
D4 4.92
hERG 3
H1 130
NK1 1000

Sertindole is metabolized in the body to dehydrosertindole.[10]

Safety and status

USA

Abbott Labs first applied for U.S. Food and Drug Administration (FDA) approval for sertindole in 1996,[11] but withdrew this application in 1998 following concerns over the increased risk of sudden death from QTc prolongation.[12] In a trial of 2000 patients on taking sertindole, 27 patients died unexpectedly, including 13 sudden deaths.[13] Lundbeck cites the results of the Sertindole Cohort Prospective (SCoP) study of 10,000 patients to support its claim that although sertindole does increase the QTc interval, this is not associated with increased rates of cardiac arrhythmias, and that patients on sertindole had the same overall mortality rate as those on risperidone.[14] Nevertheless in April 2009 an FDA advisory panel voted 13-0 that sertindole was effective in the treatment of schizophrenia but 12-1 that it had not been shown to be acceptably safe.[15] As of October 2010, the drug has not been approved by the FDA for use in the USA.[16]

Europe

In Europe, sertindole was approved and marketed in 19 countries from 1996,[13] but its marketing authorization was suspended by the European Medicines Agency in 1998[17] and the drug was withdrawn from the market. In 2002, based on new data, the EMA's CHMP suggested that Sertindole could be reintroduced for restricted use in clinical trials, with strong safeguards including extensive contraindications and warnings for patients at risk of cardiac dysrhythmias, a recommended reduction in maximum dose from 24 mg to 20 mg in all but exceptional cases, and extensive ECG monitoring requirement before and during treatment.[18][19]

References

  1. 1 2 Karamatskos, E; Lambert, M; Mulert, C; Naber, D (November 2012). "Drug safety and efficacy evaluation of sertindole for schizophrenia". Expert Opinion on Drug Safety 11 (6): 1047–1062. doi:10.1517/14740338.2012.726984. PMID 22992213.
  2. 1 2 3 4 5 6 7 8 "PRODUCT INFORMATION SERDOLECT® TABLETS" (PDF). TGA eBusiness Services. Lundbeck Australia Pty Ltd. 16 January 2013. Retrieved 27 October 2013.
  3. ↑ Juruena, MF; de Sena, EP; de Oliveira, IR (May 2011). "Sertindole in the Management of Schizophrenia" (PDF). Journal of Central Nervous System Disease 3: 75–85. doi:10.4137/JCNSD.S5729. PMC 3663609. PMID 23861640.
  4. ↑ Lewis, R; Bagnall, AM; Leitner, M (Jul 20, 2005). "Sertindole for schizophrenia.". Cochrane database of systematic reviews (Online) (3): CD001715. doi:10.1002/14651858.CD001715.pub2. PMID 16034864.
  5. ↑ Juruena, Mario F.; de Sena, Eduardo Pondé; de Oliveira, Irismar Reis (2011-01-01). "Sertindole in the management of schizophrenia". Journal of Central Nervous System Disease 3: 75–85. doi:10.4137/JCNSD.S5729. ISSN 1179-5735. PMC 3663609. PMID 23861640.
  6. 1 2 Taylor, D; Paton, C; Shitij, K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97948-8.
  7. 1 2 3 4 5 Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
  8. ↑ Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 27 October 2013.
  9. 1 2 3 4 5 Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
  10. ↑ http://www.trc-canada.com/detail.php?CatNum=D230095&CAS=173294-84-3&Chemical_Name=Dehydrosertindole&Mol_Formula=C24H24ClFN4O&Synonym=1-%5B2-%5B4-%5B5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl%5D-1-piperidinyl%5Dethyl%5D-1,3-dihydro-2H-Imidazol-2-one;%20Lu%2028-092
  11. ↑ Zeneca's Seroquel Nears Market Approval - The Pharma Letter, 16 July 1997
  12. ↑ Abbott Labs Withdraws Sertindole NDA Sertindole - The Pharma Letter, 12 Jan 1998
  13. 1 2 "WHO Pharmaceuticals Newsletter 1998, No. 03&04: Regulatory actions: Sertindole - approval application withdrawn".
  14. ↑ FDA Advisory Committee provides opinion on Serdolect for the treatment of schizophrenia - Lundbeck press release, 8 Apr 2009
  15. ↑ Food and Drug Administration; Minutes of the Psychphamacological Drugs Advisory Committee, 7 Apr 2009
  16. ↑
  17. ↑ EU CHMP recommends lifting ban on atypical antipsychotic Serdolect (sertindole) - National electronic Library for Medicines, NHS
  18. ↑ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS OPINION FOLLOWING AN ARTICLE 36 REFERRAL: SERTINDOLE - European Medicines Agency, 13 Sep 2002
  19. ↑ Restricted re-introduction of the atypical antipsychotic sertindole (Serdolect) - MHRA, 2002
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.